应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。
关闭
NVO 诺和诺德
休市中 04-02 16:00:00 EDT
36.98
+0.50
+1.37%
盘后
36.87
-0.11
-0.30%
19:59 EDT
最高
36.98
最低
35.63
成交量
1,470万
今开
36.09
昨收
36.48
日振幅
3.71%
总市值
1,642亿
流通市值
1,179亿
总股本
44.39亿
成交额
5.37亿
换手率
0.46%
流通股本
31.88亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
巨头之战：礼来口服减肥药获批，诺和诺德抛出数据回应
21世纪经济报道 · 04-03 19:00
巨头之战：礼来口服减肥药获批，诺和诺德抛出数据回应
诺和诺德：Wegovy口服片剂表现优于礼来的口服GLP-1药物
格隆汇 · 04-02 21:18
诺和诺德：Wegovy口服片剂表现优于礼来的口服GLP-1药物
诺和诺德称：口服版Wegovy减肥效果优于礼来GLP‑1口服药
环球市场播报 · 04-02 21:02
诺和诺德称：口服版Wegovy减肥效果优于礼来GLP‑1口服药
消息称特朗普拟对部分制药企业征收新关税
老虎资讯综合 · 04-02 07:45
消息称特朗普拟对部分制药企业征收新关税
礼来口服减肥药获批 加剧与诺和诺德竞争
格隆汇 · 04-01 23:54
礼来口服减肥药获批 加剧与诺和诺德竞争
诺和诺德(NVO)推出Wegovy折扣订阅计划 旨在降价抢攻减肥药市场
金吾财讯 · 03-31
诺和诺德(NVO)推出Wegovy折扣订阅计划 旨在降价抢攻减肥药市场
诺和诺德：Wegovy订阅计划将于3月31日起通过Ro、WeightWatchers和LifeMD提供
美股速递 · 03-31
诺和诺德：Wegovy订阅计划将于3月31日起通过Ro、WeightWatchers和LifeMD提供
诺和诺德：Wegovy口服药9毫克及25毫克剂量推出订阅计划，3个月套餐每月289美元、6个月套餐每月269美元、12个月套餐每月249美元
美股速递 · 03-31
诺和诺德：Wegovy口服药9毫克及25毫克剂量推出订阅计划，3个月套餐每月289美元、6个月套餐每月269美元、12个月套餐每月249美元
诺和诺德每周一次基础胰岛素制剂Awiqli获美国FDA批准
格隆汇 · 03-28
诺和诺德每周一次基础胰岛素制剂Awiqli获美国FDA批准
诺和诺德“周制剂”胰岛素获美国FDA批准上市
金吾财讯 · 03-27
诺和诺德“周制剂”胰岛素获美国FDA批准上市
美股异动丨诺和诺德盘前涨超2%，“周制剂”胰岛素在美获批上市
格隆汇 · 03-27
美股异动丨诺和诺德盘前涨超2%，“周制剂”胰岛素在美获批上市
糖果巨头CEO加盟减重药巨头诺和诺德
格隆汇 · 03-27
糖果巨头CEO加盟减重药巨头诺和诺德
诺和诺德任命玛氏公司CEO为董事会观察员
格隆汇 · 03-26
诺和诺德任命玛氏公司CEO为董事会观察员
诺和诺德Wegovy高剂量版本获美国FDA批准，将于4月上市
格隆汇 · 03-20
诺和诺德Wegovy高剂量版本获美国FDA批准，将于4月上市
诺和诺德(NVO.US)拟在日本拓展减肥药市场，“曲线入市“瞄准自费患者蓝海
智通财经 · 03-19
诺和诺德(NVO.US)拟在日本拓展减肥药市场，“曲线入市“瞄准自费患者蓝海
诺和诺德据悉正寻求拓宽日本患者获取减肥药的渠道
格隆汇 · 03-19
诺和诺德据悉正寻求拓宽日本患者获取减肥药的渠道
FDA 连发多份 CRL，开年大批新药上市申请已遭拒
制药网 · 03-11
FDA 连发多份 CRL，开年大批新药上市申请已遭拒
诺和诺德旗下“问题”工厂，又一家药企遭殃
生物制药小编 · 03-11
诺和诺德旗下“问题”工厂，又一家药企遭殃
Hims & Hers与诺和诺德达成和解
环球市场播报 · 03-10
Hims & Hers与诺和诺德达成和解
3月10日美股成交额前20：HIMS与诺和诺德达成合作，股价大涨逾40%
环球市场播报 · 03-10
3月10日美股成交额前20：HIMS与诺和诺德达成合作，股价大涨逾40%
加载更多
公司概况
公司名称：
诺和诺德
所属市场：
NYSE
上市日期：
--
主营业务：
Novo Nordisk A/S成立于1989年，由两家丹麦公司Nordisk Gentofte A/S和Novo Industri A/S合并而成。该公司是一家全球性的医疗保健公司，也是肥胖和糖尿病护理、制造和营销包括GLP-1受体激动剂和现代胰岛素在内的医药产品的世界领先企业。总部位于丹麦，业务遍及约80个国家，产品销往约170个国家。
发行价格：
--
{"stockData":{"symbol":"NVO","market":"US","secType":"STK","nameCN":"诺和诺德","latestPrice":36.98,"timestamp":1775160000000,"preClose":36.48,"halted":0,"volume":14695847,"hourTrading":{"tag":"盘后","latestPrice":36.87,"preClose":36.98,"latestTime":"19:59 EDT","volume":229931,"amount":8494516.9233,"timestamp":1775174390004,"change":-0.11,"changeRate":-0.002975,"amplitude":0.004056},"delay":0,"changeRate":0.013706140350877194,"floatShares":3187922885,"shares":4439052849,"eps":3.620568,"marketStatus":"休市中","change":0.5,"latestTime":"04-02 16:00:00 EDT","open":36.09,"high":36.98,"low":35.625,"amount":536529428.976005,"amplitude":0.037144,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":3.620568,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1775462400000},"marketStatusCode":7,"adr":1,"adrRate":1,"listingDate":363499200000,"exchange":"NYSE","adjPreClose":36.48,"dividendRate":0.046564,"preHourTrading":{"tag":"盘前","latestPrice":36.09,"preClose":36.48,"latestTime":"09:29 EDT","volume":198774,"amount":7143100.125138,"timestamp":1775136598079,"change":-0.39,"changeRate":-0.010691,"amplitude":0.021919},"postHourTrading":{"tag":"盘后","latestPrice":36.87,"preClose":36.98,"latestTime":"19:59 EDT","volume":229931,"amount":8494516.9233,"timestamp":1775174390004,"change":-0.11,"changeRate":-0.002975,"amplitude":0.004056},"volumeRatio":0.767404519182236,"optionData":{"bulkOrders":[{"symbol":"NVO","call":true,"expireDate":1776398400000,"strike":"36.0","timestamp":1775153366540,"price":1.55,"volume":1499,"amount":232345,"type":"-"}]},"impliedVol":0.5357,"impliedVolPercentile":0.6175},"requestUrl":"/m/hq/s/NVO","defaultTab":"news","newsList":[{"id":"2624540736","title":"巨头之战：礼来口服减肥药获批，诺和诺德抛出数据回应","url":"https://stock-news.laohu8.com/highlight/detail?id=2624540736","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624540736?lang=zh_cn&edition=full","pubTime":"2026-04-03 19:00","pubTimestamp":1775214000,"startTime":"0","endTime":"0","summary":"4月3日，就在礼来（EliLilly）宣布其口服小分子GLP-1药物Orforglipron（商品名：Foundayo）获得FDA批准仅两天后，诺和诺德（NovoNordisk）迅速发起了反击。这家丹麦制药巨头宣布将在肥胖医学协会年会上公布ORION研究结果。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604033695090133.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604033695090133.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1917777945.USD","LU2106854487.HKD","IE00BJT1NW94.SGD","LU2471134523.USD","LU1720051017.SGD","LU2471134879.HKD","SG9999014880.SGD","LU0256863811.USD","LU0006306889.USD","LU2089284900.SGD","LU1974910355.USD","IE0004445015.USD","LU0079474960.USD","LU1868837136.USD","LU2491050071.SGD","LU0323591593.USD","SGXZ51526630.SGD","LU2471134796.USD","LU0266013472.USD","LU2746668974.SGD","LU2264538146.SGD","LU1989771016.USD","BK4534","LU1868836914.USD","LU2462157665.USD","IE00B1BXHZ80.USD","LU0882574055.USD","SGXZ99366536.SGD","LU1712237335.SGD","LU0354030511.USD","IE00BN29S564.USD","LU0122379950.USD","LU1623119135.USD","LU2750360997.AUD","LU0109394709.USD","LU1232071149.USD","SG9999018857.SGD","IE00BJJMRX11.SGD","LU1983299246.USD","IE00B1XK9C88.USD","BK4588","IE00B2B36J28.USD","LU1035775433.USD","LU2360106947.USD","LU0198837287.USD","LU0096364046.USD","IE00BKPKM429.USD","LU2361045086.USD","LU2357305700.SGD","LU2552382215.SGD","NVO","SGXZ81514606.USD","SG9999014914.USD","IE00B7KXQ091.USD","IE00BKDWB100.SGD","LU1629891620.HKD","LU1868836591.USD","LU0061475181.USD","SG9999015978.USD","LU2168563687.JPY","LU2756315664.SGD","LU1720051108.HKD","SG9999001176.SGD","LU0320765992.SGD","LU1280957306.USD","LU0109391861.USD","LU1267930730.SGD","LU2108987350.USD","LU0354030438.USD","BK4581","LU0316494557.USD","LU2063271972.USD","LU2468319806.SGD","LU0943347566.SGD","LU0094547139.USD","LU2471134952.CNY","LU2087625088.SGD","LU2756315318.SGD","LU2602419157.SGD","LU1069344957.HKD","IE00BFSS8Q28.SGD","LU2168564495.EUR","LU0466842654.USD","LU2361044949.HKD","IE00BJLML261.HKD","LU0238689110.USD","LU2237443382.USD","LU2417539215.USD","LU0820561818.USD","LU0158827948.USD","LU1548497426.USD","LU1093756325.SGD","LU1057294990.SGD","IE00BZ1G4Q59.USD","LU0114720955.EUR","LU0106261372.USD","LU0640476718.USD","BK4516","LU0823416689.USD","IE00BJJMRY28.SGD","LU0058720904.USD","LU2089984988.USD","LU2213496289.HKD","IE00BFSS7M15.SGD","LU0234572021.USD","LU2552382132.HKD","LU2028103732.USD","ELIL","BK4533","LLYX","LU0256863902.USD","LU0672654240.SGD","LU2211815571.USD","LU0210536198.USD","LU0471298777.SGD","LU1093756168.USD","LU1868836757.USD","LU2265009873.SGD","LU2746668461.USD","LU2750360641.GBP","IE0005OL40V9.USD","LU0889565916.HKD","LU0820561909.HKD","LU0353189680.USD","LU2237443549.SGD","LU1366192091.USD","LU2023250330.USD","LU2236285917.USD","LU2491050154.USD","SG9999013999.USD","LU2111349929.HKD","LU2896262040.SGD","LU0225283273.USD","SG9999001176.USD","LU1551013425.SGD","LU2456880835.USD","LU0417517546.SGD","LU2552382058.USD","LU0786609619.USD","ELIS","SG9999015945.SGD","LU0471298694.HKD","IE0001KFT4U8.USD","LU0708995401.HKD","LU2324357040.USD","IE0002141913.USD","LU1061106388.HKD","LU0683600562.USD","LU1127390331.HKD","LU2237443978.SGD","SG9999014906.USD","IE00BKVL7J92.USD","LU0385154629.USD","LU0882574139.USD","LU0320765059.SGD","LU0097036916.USD","LU1064131342.USD","LU1804176565.USD","LU2237438978.USD","LU0456855351.SGD","LU2023251221.USD","LU0289739699.SGD","SGXZ57979304.SGD","BK4532","LU1291159041.SGD","NVOX","IE0009355771.USD","LU1145028129.USD","LU2271345857.HKD","LU0823434740.USD","LU0964807845.USD","LU0154236417.USD","LU2168564065.EUR","LU1323610961.USD","LU0823434583.USD","LU2168564149.EUR","LU0432979614.USD","IE00BFTCPJ56.SGD","LU1814569148.SGD","LU2491049909.HKD","LU2089283258.USD","LU1551013342.USD","IE00BK4W5M84.HKD","LU0820562030.AUD","LU0203202063.USD","LU2237443622.USD","LU0353189763.USD","LLYZ","SG9999018865.SGD","LU2361044865.SGD","SG9999017495.SGD","LU2168564222.USD","BK4599","LU2112291526.USD","SG9999015986.USD","LU1988902786.USD","LLII","LU0203201768.USD","LU0787776722.HKD","LU2237443465.HKD","NVOH","LU2023250504.SGD","LU2237443895.HKD","BK4007","IE00B775H168.HKD","IE00BJJMRZ35.SGD","LU0689472784.USD","LU1868837300.USD","IE00B4R5TH58.HKD","LLY","SG9999014898.SGD","IE00B4JS1V06.HKD","SGXZ31699556.SGD","LU0158827781.USD","IE00BK4W5L77.USD","IE0004445239.USD","LU1023059063.AUD","LU2461242641.AUD","GB00BDT5M118.USD","SG9999015952.SGD","IE00BWXC8680.SGD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624504856","title":"诺和诺德：Wegovy口服片剂表现优于礼来的口服GLP-1药物","url":"https://stock-news.laohu8.com/highlight/detail?id=2624504856","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624504856?lang=zh_cn&edition=full","pubTime":"2026-04-02 21:18","pubTimestamp":1775135925,"startTime":"0","endTime":"0","summary":"表现出更明显的减重效果。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["NVO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624501755","title":"诺和诺德称：口服版Wegovy减肥效果优于礼来GLP‑1口服药","url":"https://stock-news.laohu8.com/highlight/detail?id=2624501755","media":"环球市场播报","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624501755?lang=zh_cn&edition=full","pubTime":"2026-04-02 21:02","pubTimestamp":1775134920,"startTime":"0","endTime":"0","summary":"诺和诺德周四表示，口服版 Wegovy 的平均减重效果显著优于礼来本周刚获批的竞品药物 Foundayo。诺和诺德称，另一项分析显示，84% 的患者更偏好与 Wegovy 相似的药物特性，而非 Foundayo。 此前研究显示，口服 Wegovy 平均减重幅度达16.6%；而坚持完成疗程的患者服用 Foundayo 后，平均减重约12.4%。 自 1 月初口服 Wegovy 在美国上市以来，处方量飙升，已有超 60 万名患者开始服用。 诺和诺德周四称，最新研究结果表明，口服 Wegovy 具备差异化竞争力。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-04-02/doc-inhtcnfs0874567.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4588","LU0114720955.EUR","LU1069344957.HKD","LU1145028129.USD","LU2236285917.USD","IE00BJJMRY28.SGD","LU2023250330.USD","LU2237443465.HKD","LU0820562030.AUD","LU0006306889.USD","IE0005OL40V9.USD","GB00BDT5M118.USD","LU1548497426.USD","LU1868836591.USD","LU1983299246.USD","LLYX","BK4516","LU2417539215.USD","LU0882574139.USD","LU2023250504.SGD","LU0820561909.HKD","LU0256863811.USD","SGXZ81514606.USD","IE00B2B36J28.USD","SG9999015952.SGD","LU0154236417.USD","LU2106854487.HKD","LU2361045086.USD","LU1804176565.USD","LU2461242641.AUD","BK4590","LU0385154629.USD","IE00BJJMRZ35.SGD","LU0823434583.USD","LU0943347566.SGD","LU0096364046.USD","LU0353189763.USD","IE0002141913.USD","LU1127390331.HKD","LU1323610961.USD","LU1023059063.AUD","LU1551013425.SGD","LU1868837136.USD","LU1868837300.USD","IE00B7KXQ091.USD","LU0683600562.USD","LU2168563687.JPY","LU2213496289.HKD","LU0354030438.USD","LU0689472784.USD","SG9999015945.SGD","LU2756315664.SGD","BK4585","LU1629891620.HKD","SG9999017495.SGD","SG9999018857.SGD","IE00BKDWB100.SGD","LU0061475181.USD","LU2361044949.HKD","LU2471134952.CNY","LU2468319806.SGD","LU1366192091.USD","LU2265009873.SGD","LU2089284900.SGD","LU0225283273.USD","LU0158827948.USD","LU0266013472.USD","LU2112291526.USD","IE00BK4W5M84.HKD","LU0234572021.USD","LU0823434740.USD","LU1974910355.USD","SG9999014914.USD","LU0203201768.USD","NVO","LU1064131342.USD","SGXZ99366536.SGD","LLII","LU0640476718.USD","LU1093756325.SGD","LU2089984988.USD","LU0320765059.SGD","LU1291159041.SGD","LU2471134796.USD","IE00B1XK9C88.USD","IE00BJT1NW94.SGD","LU2108987350.USD","LU1061106388.HKD","IE00BZ1G4Q59.USD","BK4007","IE00B1BXHZ80.USD","LU2237438978.USD","LU2237443895.HKD","LU2896262040.SGD","LU2471134523.USD","LU0320765992.SGD","LU0708995401.HKD","LU2237443978.SGD","LU0417517546.SGD","IE00BJJMRX11.SGD","BK4533","LU0203202063.USD","LU0097036916.USD","LU0058720904.USD","ELIS","LU0432979614.USD","LU2471134879.HKD","LU1267930730.SGD","LU1917777945.USD","LU2602419157.SGD","LU1623119135.USD","LU2237443382.USD","LU2750360997.AUD","IE00BJLML261.HKD","SG9999015986.USD","LU2111349929.HKD","SG9999014898.SGD","LU0198837287.USD","LU0964807845.USD","SGXZ51526630.SGD","LU2023251221.USD","LU1035775433.USD","LU2168564495.EUR","LU1868836914.USD","NVOH","LU0094547139.USD","LU1093756168.USD","LU2324357040.USD","LU2168564222.USD","LU0353189680.USD","IE00B4R5TH58.HKD","SG9999015978.USD","LU1720051017.SGD","IE00BN29S564.USD","LU0471298777.SGD","LU2357305700.SGD","LU2552382132.HKD","IE0004445239.USD","LU2756315318.SGD","LU2360106947.USD","IE00B775H168.HKD","LU1232071149.USD","LU2456880835.USD","LU2746668974.SGD","IE0009355771.USD","LU1057294990.SGD","LU1551013342.USD","LU2491049909.HKD","SGXZ57979304.SGD","LU0109394709.USD","LU1868836757.USD","LU1720051108.HKD","LU0079474960.USD","BK4534","SGXZ31699556.SGD","IE00B4JS1V06.HKD","LU2552382058.USD","LU2746668461.USD","LU0256863902.USD","LU0456855351.SGD","LU2271345857.HKD","LU0471298694.HKD","BK4599","LU0122379950.USD","LU2491050154.USD","LLY","LU0466842654.USD","LU1280957306.USD","LU0106261372.USD","LU2168564065.EUR","LU2211815571.USD","SG9999014880.SGD","IE0001KFT4U8.USD","LU0109391861.USD","IE00BK4W5L77.USD","LU0882574055.USD","NVOX","BK4532","LU0289739699.SGD","SG9999018865.SGD","LU0323591593.USD","LU0787776722.HKD","LU0820561818.USD","LU2087625088.SGD","LU1712237335.SGD","LU1814569148.SGD","LU2491050071.SGD","LU2063271972.USD","LU0823416689.USD","LU1989771016.USD","LU2028103732.USD","LU2237443622.USD","LU0786609619.USD","LLYZ","LU2264538146.SGD","LU2552382215.SGD","SG9999013999.USD","LU0158827781.USD","LU2462157665.USD","SG9999001176.SGD","IE00BFSS8Q28.SGD","IE00BKPKM429.USD","LU2237443549.SGD","IE00BFTCPJ56.SGD","LU0238689110.USD","IE00BFSS7M15.SGD","LU2750360641.GBP","LU2089283258.USD","LU1988902786.USD","LU0210536198.USD","IE0004445015.USD","IE00BWXC8680.SGD","LU0889565916.HKD","BK4581","BK4144","SG9999014906.USD","LU2361044865.SGD","LU0672654240.SGD","IE00BKVL7J92.USD","LU0354030511.USD","SG9999001176.USD","ELIL","LU2168564149.EUR","LU0316494557.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156657448","title":"消息称特朗普拟对部分制药企业征收新关税","url":"https://stock-news.laohu8.com/highlight/detail?id=1156657448","media":"老虎资讯综合","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1156657448?lang=zh_cn&edition=full","pubTime":"2026-04-02 07:45","pubTimestamp":1775087120,"startTime":"0","endTime":"0","summary":"某些药物和疾病类别也可能获得豁免。","market":"us","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"558a26cfa5754234b2e7f202aad8ac05","theme_name":"热榜No.3 · 特朗普最新动态","theme_type":2,"isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LLY","NVO","PFE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624510807","title":"礼来口服减肥药获批 加剧与诺和诺德竞争","url":"https://stock-news.laohu8.com/highlight/detail?id=2624510807","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624510807?lang=zh_cn&edition=full","pubTime":"2026-04-01 23:54","pubTimestamp":1775058899,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"ce4b7877932b5a888416bb320979bf5f","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["IE00BJJMRZ35.SGD","LU1551013425.SGD","LU0289739699.SGD","LU2237443549.SGD","LU1291159041.SGD","BK4599","LU2089984988.USD","LU0320765992.SGD","LU2471134952.CNY","LU2023250504.SGD","IE00B4R5TH58.HKD","LU0256863902.USD","LU1366192091.USD","SGXZ51526630.SGD","LU2361044865.SGD","LU2361045086.USD","LU1267930730.SGD","LU2361044949.HKD","IE0002141913.USD","IE00BKVL7J92.USD","LU0820561909.HKD","IE00BFTCPJ56.SGD","LU2602419157.SGD","LU0943347566.SGD","LU1127390331.HKD","IE00BJJMRX11.SGD","LU0466842654.USD","LU0683600562.USD","LU0225283273.USD","LU1868837136.USD","LU2468319806.SGD","LU0823434740.USD","LU0266013472.USD","NVO","LU0210536198.USD","IE00B4JS1V06.HKD","LU2023251221.USD","LU2471134879.HKD","LU0820561818.USD","IE0001KFT4U8.USD","LU1814569148.SGD","IE00BKPKM429.USD","LU0417517546.SGD","LU1023059063.AUD","LU0432979614.USD","IE0009355771.USD","LU0234572021.USD","LU0320765059.SGD","LU1868836591.USD","LU1323610961.USD","LU2089284900.SGD","LU1548497426.USD","LU2168564149.EUR","LU2236285917.USD","LU2491050154.USD","LU0106261372.USD","IE0004445239.USD","LU2089283258.USD","LU2237443622.USD","LU2106854487.HKD","LU0154236417.USD","IE00B775H168.HKD","LU0689472784.USD","LU0097036916.USD","IE00B1XK9C88.USD","LU2360106947.USD","LU2491049909.HKD","SG9999015952.SGD","BK4534","LU2491050071.SGD","IE00BJJMRY28.SGD","BK4532","LU0323591593.USD","LU1974910355.USD","IE00BWXC8680.SGD","LU2168564065.EUR","IE00BFSS7M15.SGD","IE00BFSS8Q28.SGD","IE00B2B36J28.USD","LU2265009873.SGD","LU2357305700.SGD","LU2237438978.USD","LU1868837300.USD","IE00BN29S564.USD","LU2213496289.HKD","LLYX","IE00B1BXHZ80.USD","LU1093756325.SGD","LU1145028129.USD","LU1983299246.USD","LU0316494557.USD","LU1917777945.USD","LU0889565916.HKD","LU0096364046.USD","LU1069344957.HKD","LU0058720904.USD","LU2237443382.USD","LU2456880835.USD","LU1804176565.USD","IE00BK4W5M84.HKD","LU1720051017.SGD","LU2168564495.EUR","LU0456855351.SGD","SG9999018865.SGD","LU2750360641.GBP","LU2324357040.USD","SGXZ99366536.SGD","LU0158827781.USD","LU2063271972.USD","BK4588","LU2896262040.SGD","BK4581","LU2264538146.SGD","LU2462157665.USD","LU2168563687.JPY","LLY","IE00BZ1G4Q59.USD","LU2168564222.USD","LU0353189763.USD","SG9999015945.SGD","LU1868836757.USD","LU2237443465.HKD","LU2756315664.SGD","IE00BK4W5L77.USD","LU0353189680.USD","LU1551013342.USD","SG9999001176.SGD","LU0823434583.USD","LU1720051108.HKD","LU1989771016.USD","SG9999001176.USD","IE00BJLML261.HKD","NVOH","LU2111349929.HKD","LU0640476718.USD","LU0708995401.HKD","LLII","LU0006306889.USD","LU2237443978.SGD","BK4516","LU0964807845.USD","LU2237443895.HKD","LU2552382215.SGD","LU0471298694.HKD","LU0203201768.USD","SG9999014906.USD","ELIS","LU2087625088.SGD","SG9999013999.USD","LU2108987350.USD","LU0354030511.USD","LU0823416689.USD","LU1623119135.USD","LU1057294990.SGD","LU1629891620.HKD","IE0004445015.USD","LU2471134796.USD","LU0109391861.USD","NVOX","LU2750360997.AUD","LU0158827948.USD","LU0354030438.USD","IE00BJT1NW94.SGD","LU2746668461.USD","LU2471134523.USD","SG9999014914.USD","LU2417539215.USD","LU1035775433.USD","LU0786609619.USD","IE00BKDWB100.SGD","LU1232071149.USD","LU0882574139.USD","SG9999017495.SGD","LU0820562030.AUD","LU2271345857.HKD","LU1988902786.USD","LU2756315318.SGD","SGXZ57979304.SGD","LU1280957306.USD","LU2112291526.USD","ELIL","LU2211815571.USD","LU0238689110.USD","LU0109394709.USD","LU1712237335.SGD","LU2461242641.AUD","LU1868836914.USD","SG9999014880.SGD","GB00BDT5M118.USD","SG9999015986.USD","LU1064131342.USD","LU1093756168.USD","LU0471298777.SGD","LU0114720955.EUR","LU0385154629.USD","LU1061106388.HKD","LU0061475181.USD","LU0882574055.USD","SGXZ31699556.SGD","SG9999015978.USD","LU2028103732.USD","BK4007","LU0203202063.USD","LLYZ","BK4585","BK4533","IE0005OL40V9.USD","LU0094547139.USD","LU0672654240.SGD","LU2746668974.SGD","LU0256863811.USD","LU2552382058.USD","IE00B7KXQ091.USD","LU2552382132.HKD","LU2023250330.USD","LU0787776722.HKD","SGXZ81514606.USD","SG9999014898.SGD","LU0122379950.USD","LU0079474960.USD","LU0198837287.USD","SG9999018857.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623860535","title":"诺和诺德(NVO)推出Wegovy折扣订阅计划 旨在降价抢攻减肥药市场","url":"https://stock-news.laohu8.com/highlight/detail?id=2623860535","media":"金吾财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623860535?lang=zh_cn&edition=full","pubTime":"2026-03-31 19:53","pubTimestamp":1774957981,"startTime":"0","endTime":"0","summary":"金吾财讯 | 诺和诺德宣布，将为美国自费患者推出减肥药 Wegovy 折扣订阅计划，自周二起通过多家远程医疗平台上线，后续还将接入更多合作方。该计划按月固定收费，可选 3 至 12 个月疗程，期限越长折扣越大，自费价格较标准价低近三成，最高可节省每年1200美元。此举旨在提升药物可及性，在肥胖症药物市场争夺份额。不过市场观点认为，诺和诺德降价幅度大于礼来，或在价格竞争中处于不利地位。","market":"hk","thumbnail":"https://static.szfiu.com/news/20210625/OTU2NGE4NGJmZTIzZDc2N2YxYmJkM2MyMjUzODQzOTQ1NzY=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210625/OTU2NGE4NGJmZTIzZDc2N2YxYmJkM2MyMjUzODQzOTQ1NzY=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"298592","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0004445239.USD","LU1868836591.USD","SG9999018865.SGD","LU1868836914.USD","IE00B1BXHZ80.USD","LU2023250330.USD","LU1712237335.SGD","LU2087625088.SGD","IE00BKPKM429.USD","LU2756315318.SGD","ELIL","LU0154236417.USD","LU1868837300.USD","IE00B1XK9C88.USD","LU2746668461.USD","IE00BJJMRZ35.SGD","LU1064131342.USD","LU2896262040.SGD","LU1868837136.USD","LU2756315664.SGD","LU0354030511.USD","LU1548497426.USD","LU2361044949.HKD","LU0289739699.SGD","LU2237438978.USD","LU2361044865.SGD","LU0158827948.USD","NVO","LU0006306889.USD","LU2236285917.USD","IE00B4JS1V06.HKD","SG9999014906.USD","BK4599","SGXZ31699556.SGD","BK4533","LU2602419157.SGD","SG9999017495.SGD","SG9999014914.USD","LU0109391861.USD","LU2237443622.USD","LU2108987350.USD","LU2063271972.USD","LU1057294990.SGD","LU0106261372.USD","BK4588","LU0640476718.USD","LU1035775433.USD","BK4585","LU2237443465.HKD","LU1814569148.SGD","LU0238689110.USD","LU0889565916.HKD","LU0823416689.USD","SG9999001176.USD","IE00B2B36J28.USD","IE0009355771.USD","LU0432979614.USD","LU0203202063.USD","SG9999013999.USD","IE00BJJMRY28.SGD","LU1551013425.SGD","LU0823434740.USD","LU1917777945.USD","LU2168563687.JPY","LU2168564495.EUR","LU2264538146.SGD","IE00BJJMRX11.SGD","LU0234572021.USD","LU0109394709.USD","BK4581","LU2324357040.USD","LU2361045086.USD","IE0002141913.USD","LU1093756168.USD","LU0256863811.USD","LU2089984988.USD","LU2468319806.SGD","LU2552382132.HKD","SGXZ99366536.SGD","LU2552382058.USD","SG9999018857.SGD","LU0225283273.USD","LU2237443895.HKD","LU2456880835.USD","SGXZ51526630.SGD","LU2112291526.USD","LU0353189763.USD","LU2471134879.HKD","LU2111349929.HKD","IE00BJLML261.HKD","LU0079474960.USD","IE00BK4W5L77.USD","LU0256863902.USD","LU1366192091.USD","BK4534","LU2471134796.USD","LU0820562030.AUD","IE00B4R5TH58.HKD","IE00B775H168.HKD","LU1720051108.HKD","LU1629891620.HKD","SG9999015986.USD","LU1989771016.USD","LU0820561818.USD","LU0096364046.USD","LU0882574139.USD","IE00BZ1G4Q59.USD","IE00B7KXQ091.USD","LU0689472784.USD","LU2237443978.SGD","LU2491049909.HKD","LU1868836757.USD","LU0122379950.USD","LU2237443549.SGD","IE00BFSS7M15.SGD","LU2211815571.USD","LU0266013472.USD","LU0882574055.USD","SG9999014898.SGD","IE0001KFT4U8.USD","LU2552382215.SGD","LU1145028129.USD","IE00BJT1NW94.SGD","BK4516","LU0943347566.SGD","IE0005OL40V9.USD","LU2491050071.SGD","LU0097036916.USD","LU1983299246.USD","SG9999014880.SGD","LU0320765992.SGD","IE00BKDWB100.SGD","BK4532","LU2213496289.HKD","IE0004445015.USD","LU0094547139.USD","LU1127390331.HKD","LU2023251221.USD","LU2471134952.CNY","LU0158827781.USD","LU2746668974.SGD","NVOX","SG9999015945.SGD","IE00BFSS8Q28.SGD","IE00BFTCPJ56.SGD","LU0198837287.USD","LU2089283258.USD","LU0672654240.SGD","LU2461242641.AUD","IE00BN29S564.USD","LU0964807845.USD","LU1804176565.USD","SG9999001176.SGD","LU0417517546.SGD","LU0471298777.SGD","LU0786609619.USD","LU2028103732.USD","LU2089284900.SGD","LU0061475181.USD","SG9999015952.SGD","LU2750360997.AUD","LU0385154629.USD","LU0708995401.HKD","LU2023250504.SGD","LLII","LU0058720904.USD","LU0354030438.USD","LU0820561909.HKD","LU0114720955.EUR","LU1069344957.HKD","LU2357305700.SGD","ELIS","LU0683600562.USD","LU1267930730.SGD","LU1323610961.USD","LU2417539215.USD","LU0203201768.USD","IE00BWXC8680.SGD","LU1280957306.USD","LU1023059063.AUD","GB00BDT5M118.USD","LU2491050154.USD","LU0210536198.USD","LU2168564222.USD","SGXZ81514606.USD","LU2471134523.USD","LLYX","LU1988902786.USD","LU0323591593.USD","LU0471298694.HKD","LU2271345857.HKD","LU2360106947.USD","LU0316494557.USD","LU2265009873.SGD","BK4007","LU2750360641.GBP","LU0456855351.SGD","LU1093756325.SGD","LU0320765059.SGD","LU1974910355.USD","LU2168564149.EUR","SG9999015978.USD","SGXZ57979304.SGD","LU1720051017.SGD","NVOH","IE00BKVL7J92.USD","IE00BK4W5M84.HKD","LLYZ","LU0823434583.USD","LU1551013342.USD","LU1623119135.USD","LU0353189680.USD","LU2462157665.USD","LU2168564065.EUR","LU1291159041.SGD","LU1232071149.USD","LU2237443382.USD","LU0787776722.HKD","LU1061106388.HKD","LU0466842654.USD","LU2106854487.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136041471","title":"诺和诺德：Wegovy订阅计划将于3月31日起通过Ro、WeightWatchers和LifeMD提供","url":"https://stock-news.laohu8.com/highlight/detail?id=1136041471","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1136041471?lang=zh_cn&edition=full","pubTime":"2026-03-31 19:34","pubTimestamp":1774956843,"startTime":"0","endTime":"0","summary":"诺和诺德公司宣布，其备受关注的减肥药物Wegovy订阅服务将从3月31日起正式上线。该计划将通过数字健康平台Ro、体重管理服务商WeightWatchers以及远程医疗提供商LifeMD向用户开放。\n这一举措标志着诺和诺德在拓宽Wegovy可及性方面迈出重要一步。通过与合作方联手，患者将能更便捷地获得这款GLP-1受体激动剂药物的专业指导和支持服务。\n订阅计划的推出正值减肥药物市场需求激增之际。分析认为，这种创新服务模式有望帮助更多肥胖症患者获得规范治疗，同时强化诺和诺德在代谢疾病领域的市场地位。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"ea115adc665c74e6a4a5582f9333b9fe","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HIMZ","HMYY","HIYY","BK4196","HIMY","NVO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111906858","title":"诺和诺德：Wegovy口服药9毫克及25毫克剂量推出订阅计划，3个月套餐每月289美元、6个月套餐每月269美元、12个月套餐每月249美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1111906858","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1111906858?lang=zh_cn&edition=full","pubTime":"2026-03-31 19:33","pubTimestamp":1774956827,"startTime":"0","endTime":"0","summary":"诺和诺德（Novo Nordisk）近日宣布，其备受关注的Wegovy口服药已推出灵活订阅方案，涵盖9毫克和25毫克两种剂量规格。用户现可选择3个月、6个月或12个月的不同订阅周期，享受阶梯式价格优惠：3个月套餐月费为289美元，6个月套餐月费降至269美元，而12个月长期订阅更可享每月249美元的超值价格。这一订阅模式旨在为长期体重管理需求者提供更可持续的经济选择，同时强化药物使用的连续性。随着Wegovy口服版本在减重市场的持续渗透，诺和诺德正通过多元化的支付策略进一步扩大其用户基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"ea115adc665c74e6a4a5582f9333b9fe","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HMYY","HIMY","BK4196","HIMZ","NVO","HIYY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622538856","title":"诺和诺德每周一次基础胰岛素制剂Awiqli获美国FDA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2622538856","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622538856?lang=zh_cn&edition=full","pubTime":"2026-03-28 14:06","pubTimestamp":1774678001,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LU0154236417.USD","NVOH","BK4585","BK4599","LU1093756168.USD","BK4007","NVO","IE00BZ1G4Q59.USD","NVOX","BK4588","BK4532","IE00BKVL7J92.USD","LU1093756325.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622282640","title":"诺和诺德“周制剂”胰岛素获美国FDA批准上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2622282640","media":"金吾财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622282640?lang=zh_cn&edition=full","pubTime":"2026-03-27 19:52","pubTimestamp":1774612372,"startTime":"0","endTime":"0","summary":"金吾财讯 | 诺和诺德宣布，美国食品药品监督管理局(FDA)正式批准其Awiqli(依柯胰岛素注射液:700单位/毫升)上市。该药物主要作为饮食和运动的辅助手段，旨在帮助改善成人2型糖尿病患者的血糖控制。该注射液获批上升后将把每周多达七次的常规基础胰岛素注射大幅缩减至仅需一次，为患者提供了一种革命性的替代方案。","market":"sg","thumbnail":"https://static.szfiu.com/news/20210625/YzM0ZmE0OGYyYmI1ZTk0YjVmZmU4ZTU4MTIzMDA2MDU4MDg=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210625/YzM0ZmE0OGYyYmI1ZTk0YjVmZmU4ZTU4MTIzMDA2MDU4MDg=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"298464","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVO","BK4007","NVOX","IE00BZ1G4Q59.USD","BK4599","BK4532","IE00BKVL7J92.USD","LU1093756325.SGD","BK4588","LU1093756168.USD","NVOH","LU0154236417.USD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622846972","title":"美股异动丨诺和诺德盘前涨超2%，“周制剂”胰岛素在美获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2622846972","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622846972?lang=zh_cn&edition=full","pubTime":"2026-03-27 16:09","pubTimestamp":1774598948,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["NVOH","LU1093756325.SGD","IE00BKVL7J92.USD","BK4532","BK4585","BK4588","BK4599","LU1093756168.USD","NVO","LU0154236417.USD","NVOX","IE00BZ1G4Q59.USD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622148138","title":"糖果巨头CEO加盟减重药巨头诺和诺德","url":"https://stock-news.laohu8.com/highlight/detail?id=2622148138","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622148138?lang=zh_cn&edition=full","pubTime":"2026-03-27 12:01","pubTimestamp":1774584060,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["NVOX","BK4599","BK4007","IE00BZ1G4Q59.USD","BK4585","BK4588","NVOH","LU1093756325.SGD","BK4532","LU1093756168.USD","IE00BKVL7J92.USD","LU0154236417.USD","NVO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622610848","title":"诺和诺德任命玛氏公司CEO为董事会观察员","url":"https://stock-news.laohu8.com/highlight/detail?id=2622610848","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622610848?lang=zh_cn&edition=full","pubTime":"2026-03-26 23:20","pubTimestamp":1774538405,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["NVOX","BK4007","IE00BKVL7J92.USD","LU0154236417.USD","LU1093756168.USD","IE00BZ1G4Q59.USD","LU1093756325.SGD","BK4585","BK4588","BK4532","NVOH","NVO","BK4599"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620034312","title":"诺和诺德Wegovy高剂量版本获美国FDA批准，将于4月上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2620034312","media":"格隆汇","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620034312?lang=zh_cn&edition=full","pubTime":"2026-03-20 09:17","pubTimestamp":1773969440,"startTime":"0","endTime":"0","summary":"3月20日，美国食品药物管理局批准诺和诺德减重药物Wegovy的更高剂量版本。诺和诺德计划于4月推出新剂量版本，并将其定位为强化竞争力的关键产品，以对抗礼来推出的减重药Zepbound。临床数据显示，在一项为期72周的第三期试验中，7.2毫克剂量的Wegovy可使肥胖患者平均减重20.7%，而标准剂量的平均减重幅度约为15%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2026/03/20091756381989.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_highlight","symbols":["BK4588","IE00BZ1G4Q59.USD","BK4532","LU1093756168.USD","IE00BKVL7J92.USD","NVOX","LU0154236417.USD","BK4599","BK4007","LU1093756325.SGD","NVO","NVOH","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620903249","title":"诺和诺德(NVO.US)拟在日本拓展减肥药市场，“曲线入市“瞄准自费患者蓝海","url":"https://stock-news.laohu8.com/highlight/detail?id=2620903249","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620903249?lang=zh_cn&edition=full","pubTime":"2026-03-19 18:25","pubTimestamp":1773915956,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，诺和诺德公司正寻求通过瞄准愿意自费使用Wegovy等胰高血糖素样肽-1药物的患者，来扩大肥胖症治疗在日本的可及性。诺和诺德推动自费医疗的举措，反映了整个行业在渗透率不足的市场扩大治疗的更广泛努力。在肥胖症和罕见病疗法的推动下，诺和诺德日本业务部门去年收入增长了5.4%。\"诺和诺德在日本的努力可能沿袭了其在美国建立的直接面向消费者的销售路径。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1416019.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["NVOH","LU1093756325.SGD","IE00BKVL7J92.USD","BK4532","BK4585","BK4588","BK4599","LU1093756168.USD","NVO","LU0154236417.USD","NVOX","IE00BZ1G4Q59.USD","BK4007"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2620431362","title":"诺和诺德据悉正寻求拓宽日本患者获取减肥药的渠道","url":"https://stock-news.laohu8.com/highlight/detail?id=2620431362","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620431362?lang=zh_cn&edition=full","pubTime":"2026-03-19 17:07","pubTimestamp":1773911228,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["IE00BZ1G4Q59.USD","BK4599","BK4585","BK4532","LU0154236417.USD","NVO","BK4588","NVOH","LU1093756325.SGD","BK4007","NVOX","IE00BKVL7J92.USD","LU1093756168.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618157119","title":"FDA 连发多份 CRL，开年大批新药上市申请已遭拒","url":"https://stock-news.laohu8.com/highlight/detail?id=2618157119","media":"制药网","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618157119?lang=zh_cn&edition=full","pubTime":"2026-03-11 14:39","pubTimestamp":1773211194,"startTime":"0","endTime":"0","summary":"2026年以来，全球医药企业就遭遇了FDA的CRL风暴。2月14日消息，Disc Medicine备受瞩目的候选药物Bitopertin用于治疗罕见血液病红细胞生成性卟啉症的上市申请遭到FDA拒绝。2月3日，阿斯利康公告称，美国FDA就Saphnelo用于成人系统性红斑狼疮患者皮下给药的生物制品许可申请发出完整答复函，驳回了其狼疮治疗药物的自行注射剂型上市申请。总的来说，2026 年 开年以来，已有众多新药上市申请被拒。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311144149a6b747a8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311144149a6b747a8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1815336091.USD","BK4532","LU0757428866.USD","LU0154236417.USD","BK4585","LU0029874061.USD","IE00BKVL7J92.USD","BK4599","BK4530","LU0128526141.USD","NVO","LU0390134368.USD","BK4588","NVOX","LU1093756325.SGD","NVOH","AZN","LU1093756168.USD","BK4121","IE00BFMHRM44.USD","BK4007","IE00BZ1G4Q59.USD","REGN","INCY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618963769","title":"诺和诺德旗下“问题”工厂，又一家药企遭殃","url":"https://stock-news.laohu8.com/highlight/detail?id=2618963769","media":"生物制药小编","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618963769?lang=zh_cn&edition=full","pubTime":"2026-03-11 09:20","pubTimestamp":1773192018,"startTime":"0","endTime":"0","summary":"这也是第三家因为该工厂生产设施问题而遭发CRL的药企，其中再生元最为倒霉，2025年，有两款药物皆是因其被拒。2025年10月，同样因为这家工厂的合规性问题，再生元旗下的另一款药物—预填充注射器版本HD Eylea的补充上市申请也遭到拒批，收到FDA的CRL。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311093344a45fc34a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311093344a45fc34a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","LU0154236417.USD","LU1093756325.SGD","NVO","IE00BZ1G4Q59.USD","NVOH","BK4532","IE00BKVL7J92.USD","BK4588","BK4599","BK4585","LU1093756168.USD","NVOX"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2618895342","title":"Hims & Hers与诺和诺德达成和解","url":"https://stock-news.laohu8.com/highlight/detail?id=2618895342","media":"环球市场播报","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618895342?lang=zh_cn&edition=full","pubTime":"2026-03-10 21:03","pubTimestamp":1773147780,"startTime":"0","endTime":"0","summary":"Hims & Hers与诺和诺德结束诉讼，Hims将停止推广复方胰高血糖素样肽-1药物，并通过其平台提供威戈维和奥泽匹克；Hims股价大涨。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：张俊 SF065","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-03-10/doc-inhqphnh6182604.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["NVO","BK4007","NVOX","IE00BZ1G4Q59.USD","HIMS","BK4599","BK4532","IE00BKVL7J92.USD","LU1093756325.SGD","BK4588","LU1093756168.USD","NVOH","LU0154236417.USD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618672446","title":"3月10日美股成交额前20：HIMS与诺和诺德达成合作，股价大涨逾40%","url":"https://stock-news.laohu8.com/highlight/detail?id=2618672446","media":"环球市场播报","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618672446?lang=zh_cn&edition=full","pubTime":"2026-03-10 04:48","pubTimestamp":1773089280,"startTime":"0","endTime":"0","summary":"周一美股成交额第1名英伟达收高2.72%，成交313.6亿美元。亿万富豪廖凯原周一再度增持英伟达，将其持股数量翻倍至200万股。 摩尔维持对博通的“买入”评级，将其目标价从462美元上调至470美元，意味着约42%的上涨空间。 此外，3月2日，英伟达宣布投资20亿美元并与Lumentum达成多年战略合作，包括数十亿美元采购高端激光元件的承诺，聚焦AI数据中心光学技术。 该消息公布后，诺和诺德撤销了对该公司的诉讼，标志着双方争端的结束。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"2125f643a531f294312a5aa84a9983ad","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-03-10/doc-inhqmumf6558599.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["IE00BKVL7J92.USD","IE00BZ1G4Q59.USD","LU1093756325.SGD","BK4196","HIMZ","HMYY","BK4585","HIMS","BK4588","LU1093756168.USD","BK4599","BK4532","LU0154236417.USD","HIYY","NVOX","NVOH","NVO","BK4007","HIMY"],"isVideo":false,"video":null,"gpt_icon":1}],"profile":{"websiteUrl":"http://www.novonordisk.com","stockEarnings":[{"period":"1week","weight":0.0159},{"period":"1month","weight":0.0087},{"period":"3month","weight":-0.2941},{"period":"6month","weight":-0.3798},{"period":"1year","weight":-0.4581},{"period":"ytd","weight":-0.2732}],"compareEarnings":[{"period":"1week","weight":0.0166},{"period":"1month","weight":-0.036},{"period":"3month","weight":-0.04},{"period":"6month","weight":-0.02},{"period":"1year","weight":0.1617},{"period":"ytd","weight":-0.0383}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Novo Nordisk A/S成立于1989年，由两家丹麦公司Nordisk Gentofte A/S和Novo Industri A/S合并而成。该公司是一家全球性的医疗保健公司，也是肥胖和糖尿病护理、制造和营销包括GLP-1受体激动剂和现代胰岛素在内的医药产品的世界领先企业。总部位于丹麦，业务遍及约80个国家，产品销往约170个国家。","yearOnYearQuotes":[{"month":1,"riseRate":0.533333,"avgChangeRate":0.120105},{"month":2,"riseRate":0.6,"avgChangeRate":0.019219},{"month":3,"riseRate":0.444444,"avgChangeRate":0.006415},{"month":4,"riseRate":0.622222,"avgChangeRate":0.014855},{"month":5,"riseRate":0.555556,"avgChangeRate":0.018382},{"month":6,"riseRate":0.688889,"avgChangeRate":0.026171},{"month":7,"riseRate":0.488889,"avgChangeRate":-0.001692},{"month":8,"riseRate":0.533333,"avgChangeRate":0.006145},{"month":9,"riseRate":0.555556,"avgChangeRate":-0.002979},{"month":10,"riseRate":0.488889,"avgChangeRate":-0.004606},{"month":11,"riseRate":0.6,"avgChangeRate":0.026574},{"month":12,"riseRate":0.733333,"avgChangeRate":0.048757}],"exchange":"NYSE","name":"诺和诺德","nameEN":"Novo-Nordisk A/S"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"诺和诺德(NVO)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供诺和诺德(NVO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"诺和诺德,NVO,诺和诺德股票,诺和诺德股票老虎,诺和诺德股票老虎国际,诺和诺德行情,诺和诺德股票行情,诺和诺德股价,诺和诺德股市,诺和诺德股票价格,诺和诺德股票交易,诺和诺德股票购买,诺和诺德股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"诺和诺德(NVO)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供诺和诺德(NVO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}